Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: Robert DeHaven who wrote (357)	5/20/1998 1:55:00 PM
From: James Perry	Read Replies (1) \| Respond to of 1025

Bob, John Zweinner is our experienced science maven at this site, and he also is excellent at adding the numbers. You only confirm the facts that he has long been saying. I have had enough legal experience to judge from the action of the parties (I have no resources to get copies of the Declaration, Interrogatories, Demands for Admissions of Fact, etc., from the Clerk of Court, and I refer to their demeanor and the general things they have done in the conduct of management) that Igen will win the litigation in a walk. Not only can Roche not afford to lose Igen, nor to lose that suit to Igen, but there are too many other potential players in the wings. And any evaluation which fails to consider the value of large unit sales, of which Igen has made three to date, would be woefully lacking. That, without regard for the potential of the POC device. I claim no expertise as a tape watcher, and would value your insights from the street, but it appears to me that subsequent to the last large purchase of stock (apparently an addition to the Soros group portfolio), the sea-saw action of the daily price and volume tends to reflect activity to "suck people out of their positions". I started buying at 6, and consider my holding as a long term position.